Eltrombopag Cholin Suppliers & Bulk Manufacturers
Available Forms: Tablets / Oral suspension
Available Strengths: 12.5 mg, 25 mg, 50 mg, and 75 mg
Reference Brands: Promacta (USA), Revolade (EU)
Category:
Anemia
ELTROMBOPAG CHOLIN is available in Tablets / Oral suspension
and strengths such as 12.5 mg, 25 mg, 50 mg, and 75 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, ELTROMBOPAG CHOLIN is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
ELTROMBOPAG CHOLIN can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Eltrombopag, marketed under the brand names Promacta in the USA and Revolade in other countries, is an oral medication used to treat thrombocytopenia and severe aplastic anemia. It belongs to the class of thrombopoietin receptor agonists, which work by stimulating the thrombopoietin receptor on bone marrow cells, thereby promoting the production of platelets. This mechanism helps patients with abnormally low platelet counts to achieve safer levels, reducing the risk of bleeding complications.
Eltrombopag is commonly prescribed for conditions such as chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C infection. It is administered orally and is typically taken once daily, with dosing adjusted according to platelet counts and individual patient response.
Originally discovered through a research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals, eltrombopag development and marketing rights were later transferred to Novartis Pharmaceuticals. The medication has become an essential therapy for patients with platelet deficiencies, offering a non-invasive alternative to platelet transfusions and improving quality of life for individuals with chronic hematologic conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing